Tandem Diabetes Care Q3 2023 Adj EPS $(0.38) Misses $(0.34) Estimate, Sales $185.62M Miss $192.34M Estimate
Portfolio Pulse from totan@benzinga.com
Tandem Diabetes Care (NASDAQ:TNDM) reported Q3 2023 losses of $(0.38) per share, missing the analyst consensus estimate of $(0.34) by 11.76%. This is a 40.74% decrease from the same period last year. The company also reported quarterly sales of $185.62 million, missing the analyst consensus estimate of $192.34 million by 3.49%. This is a 9.25% decrease from the same period last year.
November 01, 2023 | 8:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Tandem Diabetes Care's Q3 2023 earnings missed estimates, with a larger loss per share and lower sales than expected.
Tandem Diabetes Care reported a larger loss per share and lower sales than expected for Q3 2023. This underperformance is likely to negatively impact the company's stock price in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100